Business Context and Reporting Period
This Form 8-K Current Report was filed by Aldeyra Therapeutics, Inc. on April 20, 2026. The report discloses a corporate governance event regarding the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a personnel matter and contains no financial data.
Material Changes
On April 20, 2026, Martin J. Joyce, a member of the Board of Directors, notified the company of his decision not to stand for re-election at the upcoming 2026 Annual Meeting of Stockholders. Mr. Joyce will continue to serve until his term expires at that meeting. The company stated that this decision was not the result of any disagreement with Aldeyra Therapeutics, Inc.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on operations, or discussion of risks and contingencies beyond the standard disclosure regarding the director's departure.
Key Facts for Investors
- Martin J. Joyce will not seek re-election to the Board of Directors at the 2026 Annual Meeting.
- Mr. Joyce's departure is not attributed to any disagreement with the company.
- Mr. Joyce will remain on the Board until his term expires at the Annual Meeting.
- No financial performance data is included in this specific filing.